Clinical trials: Neoplasm Recurrence
Paroxysmal Atrial Fibrillation
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease
The aim of this study is to study synergistic effect of eplerenone as Selective aldosterone receptor antagonist with amiodarone compared with amiodarone only in reducing recurrence of atrial fibrillation in patient with…
- Trial name
- NCT06168994
- Testing
- Eplerenone
- Volunteers
- 100 people
- Sponsor
- Assiut University
Leukemia, Lymphoma
Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004898
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Colorectal Cancer
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Palliative chemotherapy may help patients with advanced colorectal cancer live longer and more comfortably. PURPOSE: Randomized phase III trial to compare the effectiveness of and quality of life following three…
- Trial name
- NCT00002893
- Testing
- fluorouracil, leucovorin calcium, raltitrexed
- Where
- United Kingdom
- Volunteers
- 900 people
- Sponsor
- Medical Research Council
Ependymoma, High Grade Gliomas
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Pediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and high-grade glioma (HGG) will be included in this study of treatment with Rhenium-186 Nanoliposome (186RNL).
- Trial name
- NCT07061626
- Testing
- Rhenium-186 Nanoliposome
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Cerenome
Brain and Central Nervous System Tumors
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with…
- Trial name
- NCT00015899
- Testing
- lonafarnib
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pediatric Brain Tumor Consortium
Melanoma (Skin)
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III…
- Trial name
- NCT00002763
- Testing
- recombinant interferon alfa
- Where
- 86 sites in Austria, Belgium and 19 more
- Volunteers
- 1,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
Should Colorectal Cancer Patients be Followed After Five Years? Study of Recurrence in a Population Cohort
The results of this study will make it possible, thanks to better understanding of the natural history of colorectal cancer, to define new treatment and surveillance strategies for colorectal cancers resected with curative…
- Trial name
- NCT01904955
- Where
- France
- Volunteers
- 598 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Infant, Newborn, Neonatal SEPSIS
7 Days Versus 14 Days of Antibiotics for Neonatal Sepsis
The optimum duration of intravenous antibiotic therapy for culture-proven neonatal bacterial sepsis is not known. Current practices, ranging from 7 days to 14 days of antibiotics, are not evidence-based.
- Conditions
- Infant, Newborn, Neonatal SEPSIS, Anti-bacterial Agents, Recurrence
- Trial name
- NCT03280147
- Testing
- 7-day course of antibiotics, 14-day course of antibiotics
- Where
- 7 sites in India
- Volunteers
- 261 people
- Sponsor
- Indian Council of Medical Research
Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT00348985
- Testing
- belinostat, bortezomib, pharmacological study
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Primitive Neuroectodermal Tumor
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
Current therapies for Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors provide very limited benefit to the patient.
- Trial name
- NCT00003515
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Burzynski Research Institute
Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
- Trial name
- NCT00017160
- Testing
- doxorubicin, filgrastim, ifosfamide
- Where
- 235 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Cervical Cancer
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006482
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 34 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer.
- Conditions
- Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer
- Trial name
- NCT01502410
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- 92 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor prognosis and children with relapsed NBL have an overall 3 year survival rate of < 10%.
- Trial name
- NCT00874315
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 4 sites in United States
- Sponsor
- Nationwide Children's Hospital
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm
- Trial name
- NCT03213691
- Testing
- Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Stroke
Stroke Homecare and Recurrence Prevention
Background and Significance: Stroke is the leading cause of death in China, placing a heavy burden on patients, families, and society.
- Trial name
- SHARP (NCT06810024)
- Testing
- Home-based therapy, Standard Care (in control arm)
- Volunteers
- 1,614 people
- Sponsor
- Peking Union Medical College
Metastatic Colorectal Cancer, Recurrent Colorectal Cancer
Phase I/II Trial of Antagonism of HER in GI Cancer
Recruitment to phase I of the PANTHER trial is complete. Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.
- Trial name
- PANTHER (NCT01862003)
- Testing
- AZD8931, Irinotecan, Folinic Acid
- Where
- 4 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- University College, London
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00309959
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- 26 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.